Dry Eye Disease Market Insights and Forecast, 2019 to 2025HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 21 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Dry Eye Disease Market Insights and Forecast, 2019 to 2025GlobeNewswireJanuary 10, 2020ReblogShareTweetShareDublin, Jan. 10, 2020 (GLOBE NEWSWIRE) -- The "Global Dry Eye Disease Market 2019-2025" report has been added to ResearchAndMarkets.com's offering.
The global dry eye disease market is estimated to grow at a CAGR of 4.6% during the forecast period.Some crucial factors contributing to the growth of the market include a significant rise in the prevalence of dry eye syndrome and growing awareness campaigns for dry eye disease. There are certain awareness programs for dry eye syndrome.For instance, in May 2018, Alcon, a division of Novartis introduced the multimedia campaign, partnering with Venus Williams, a tennis champion. It is an educational campaign, which is intended to reach 30 million people suffering from dry eye syndrome in the US. Through this campaign, the company aims to promote its Systane family of lubricant eye drops.Further, in August 2016, Shire PLC introduced Eyelove campaign by featuring Jennifer Aniston (Actress). The campaign aims to promote its dry-eye disease treatment, Xiidra in the US. These kinds of campaigns are supporting to create awareness among people for dry eye syndrome and thereby leads to the adoption of treatment alternatives for the condition.Based on geography, the global dry eye disease market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The North American dry eye disease market is growing significantly owing to the emerging demand for contact lenses in the region. Asia-Pacific is estimated to witness potential growth in the market during the forecast period owing to the increasing focus of dry eye syndrome treatment providers to expand their therapeutic options to the region.Key players in the global dry eye disease market include Novartis AG, Allegan PLC, Johnson & Johnson Vision Care, Inc., Santen Pharmaceutical Co., Ltd., and Bausch Health Companies, Inc. Mergers and acquisitions, product launches, and partnerships and collaborations are some key strategies adopted by the market players to stay competitive in the market.For instance, in June 2018, Bausch + Lomb declared the introduction of Soothe Xtra Protection (XP) Preservative Free lubricant eye drops. With this product launch, the company has widened the portfolio of eye health products to meet the emerging demand for dry eye symptom relief without using preservatives.This report covers:Comprehensive research methodology of the global dry eye disease market.A detailed and extensive market overview with key analyst insights.Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.Analysis of regulations and other government policies impacting the global dry eye disease market.Insights about market determinants which are stimulating the global dry eye disease market.Detailed and extensive market segments with regional distribution of forecasted revenues.Extensive profiles and recent developments of market players.Key Topics Covered
1. Report Summary1.1. Research Methods and Tools1.2. Market Breakdown1.2.1. By Segments1.2.2. By Geography2. Market Overview and Insights2.1. Scope of the Report2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion2.3. Rules & Regulations3. Competitive Landscape3.1. Company Share Analysis3.2. Key Strategy Analysis3.3. Key Company Analysis3.3.1. Novartis AG3.3.1.1. Overview3.3.1.2. Financial Analysis3.3.1.3. SWOT Analysis3.3.1.4. Recent Developments3.3.2. Allergan PLC3.3.2.1. Overview3.3.2.2. Financial Analysis3.3.2.3. SWOT Analysis3.3.2.4. Recent Developments3.3.3. Johnson & Johnson Vision Care, Inc.3.3.3.1. Overview3.3.3.2. Financial Analysis3.3.3.3. SWOT Analysis3.3.3.4. Recent Developments3.3.4. Santen Pharmaceutical Co., Ltd.3.3.4.1. Overview3.3.4.2. Financial Analysis3.3.4.3. SWOT Analysis3.3.4.4. Recent Developments3.3.5. Bausch Health Companies, Inc.3.3.5.1. Overview3.3.5.2. Financial Analysis3.3.5.3. SWOT Analysis3.3.5.4. Recent Developments4. Market Determinants 4.1 Motivators4.2 Restraints4.3 Opportunities 5. Market Segmentation5.1. Global Dry Eye Disease Market by Type5.1.1. Aqueous 5.1.2. Evaporative5.2. Global Dry Eye Disease Market by Treatment5.2.1. Anti-Inflammatory Drugs5.2.1.1. Lifitegrast5.2.1.2. Corticosteroid5.2.1.3. Cyclosporine5.2.2. Artificial Tears5.2.3. Punctal Plug5.2.4. Secretagogue6. Regional Analysis6.1. North America6.1.1. United States6.1.2. Canada6.2. Europe6.2.1. UK6.2.2. Germany6.2.3. Italy6.2.4. Spain6.2.5. France6.2.6. Rest of Europe 6.3. Asia-Pacific6.3.1. China6.3.2. India6.3.3. Japan6.3.4. Rest of Asia-Pacific 6.4. Rest of the World7. Company Profiles7.1. AFT Pharmaceuticals7.2. Akorn, Inc. (Fresenius SE & Co. KGaA)7.3. Allergan PLC7.4. Bausch Health Companies, Inc.7.5. Beaver-Visitec International Holdings, Inc. 7.6. FCI Ophthalmics7.7. I-MED Pharma, Inc.7.8. Johnson & Johnson Vision Care, Inc.7.9. Medennium, Inc.7.10. Novaliq GmbH7.11. Novartis AG7.12. OASIS Medical, Inc.7.13. Otsuka Pharmaceutical Co. Ltd.7.14. Pfizer, Inc.7.15. Rohto Pharmaceutical Co. Ltd.7.16. Santen Pharmaceutical Co. Ltd.7.17. Scope Ophthalmics, Ltd.7.18. Sentiss Pharma Pvt. Ltd.7.19. Sun Pharmaceutical Industries, Ltd.7.20. URSAPHARM Arzneimittel GmbH7.21. VISUfarma
For more information about this report visit https://www.researchandmarkets.com/r/8eyo29Story continuesResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextSiteOne Landscape Supply adds Lowe's veteran to its C-SuiteAmerican City Business JournalsDon't Race Out To Buy Novartis AG (VTX:NOVN) Just Because It's Going Ex-DividendSimply Wall St.Sandoz to keep prices stable on coronavirus-relevant drugsReutersBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceWhat the GM strike means for the U.S. economyYahoo Finance